```markdown
---
application_number: 761225Orig1s000
applicant: Hugel, Inc
product_name: letibotulinumtoxinA injection
proprietary_name: Letybo
submission_date: 2021-03-31
complete_response_date: 2023-04-12
regulatory_contact:
  name: H. F. Van Horn III, PharmD, MBA
  title: Regulatory Project Manager
  phone: (301) 837-7389
fda_official:
  name: Julie G. Beitz, MD
  title: Director, Office of Immunology and Inflammation (OII)
action_type: Complete Response
letter_type: Other Action Letter
application_category: Biologics License Application (BLA)
resubmission_requirements: Full response required within one year or request for withdrawal may be made under 21 CFR 601.3
---

## Critical Data

- **Application Number:** 761225Orig1s000  
- **Biologics License Application (BLA):** 761225  
- **Applicant:** Hugel, Inc  
- **Authorized U.S. Agent:** Scott A. Oglesby, PhD  
- **Product:** LetibotulinumtoxinA injection  
- **Proprietary Name (Proposed):** Letybo  
- **Application Submitted On:** March 31, 2021  
- **Complete Response Letter Issued:** April 12, 2023  
- **Previous Action Letter Date:** March 31, 2022  
- **Amendment (Complete Response) Submitted:** October 6, 2022  
- **Manufacturing Facility FEI Number:** 3012163998  
- **Regulatory Contact:** H. F. Van Horn III, PharmD, MBA â€• (301) 837-7389  
- **FDA Signatory Official:** Julie G. Beitz, MD, Director, Office of Immunology and Inflammation  
- **Action Taken:** Application not approved in current form â€“ Complete Response issued  
- **Next Steps Required:** Resubmit complete response addressing deficiencies within 1 year or formally request extension

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  
## APPLICATION NUMBER: 761225Orig1s000  
### OTHER ACTION LETTERS  

---

## BLA 761225  
### COMPLETE RESPONSE  

**To:**  
Hugel, Inc  
c/o Strategic Drug Development Services, LLC  
Attention: Scott A. Oglesby, PhD  
Authorized U.S. Agent for Hugel, Inc  
6518 Green Rise Road  
Hillsborough, NC 27278  

**Dear Dr. Oglesby:**  

Please refer to your biologics license application (BLA) dated and received March 31, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for letibotulinumtoxinA injection.

We acknowledge receipt of your amendment dated October 6, 2022, which constituted a complete response to our March 31, 2022, action letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

### FACILITY INSPECTIONS

1. During a recent inspection of the Hugel, Inc. (FEI 3012163998) manufacturing and testing facility of drug substance and drug product for this application, our field investigator conveyed deficiencies to the representative of the facility.  
   Satisfactory resolution of these deficiencies is required before this application may be approved.

---

### PRESCRIBING INFORMATION

2. We reserve comment on the proposed labeling until the application is otherwise adequate.  
   We encourage you to review the labeling review resources on the [Prescription Drug Labeling Resources](https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources) and [Pregnancy and Lactation Labeling Final Rule](https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule) websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) âˆ’ a checklist of important format items from labeling regulations and guidances.

---

### CARTON AND CONTAINER LABELING

3. We reserve comment on the proposed labeling until the application is otherwise adequate.

---

### PROPRIETARY NAME

4. Please refer to correspondence dated December 28, 2022, which addresses the proposed proprietary name, Letybo. This name was found acceptable pending approval of the application in the current review cycle.  
   Please resubmit the proposed proprietary name when you respond to the application deficiencies.

---

### SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.  
2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:  
   - Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.  
   - Present tabulations of the new safety data combined with the original application data.  
   - Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described above.  
   - For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.  
3. Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.

---

### CARTON AND CONTAINER LABELING (Additional)

15. We reserve comment on the proposed labeling until the application is otherwise adequate.

---

### MEDICATION GUIDE

16. Add the following bolded statement or appropriate alternative to the carton and container labeling per 21 CFR 208.24(d):  
   **"ATTENTION PHARMACIST: Each patient is required to receive the enclosed Medication Guide."**

---

### PROPRIETARY NAME (Confirmation)

17. The proposed proprietary name, Letybo, was found conditionally acceptable pending approval of the application in the current review cycle.  
    Resubmit the proposed proprietary name when you respond to the application deficiencies.

---

### SAFETY UPDATE (Restated)

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.  
2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:  
   - Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.  
   - Present tabulations of the new safety data combined with the original application data.  
   - Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies.  
   - Provide separate tables for the frequencies of adverse events in clinical trials for indications other than the proposed indication.

---

## OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 601.3(b).  
If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 601.3(c).  
You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "**RESUBMISSION**" in large font, bolded type at the beginning of the cover letter of the submission.  
The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter.  
A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved.  
If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry:  
**Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products**

---

> The drug product may not be legally marketed until you have been notified in writing that this application is approved.

---

If you have any questions, call:

**H. F. Van Horn III, PharmD, MBA**  
Regulatory Project Manager  
ðŸ“ž (301) 837-7389

---

**Sincerely,**  
Julie G. Beitz, MD  
Director  
Office of Immunology and Inflammation (OII)  
Center for Drug Evaluation and Research

---

/s/  
**JULIE G BEITZ**  
04/12/2023 01:53:00 PM  

/s/  
**JULIE G BEITZ**  
03/31/2022 12:58:15 PM
```